Losartan 100mg tablets
Requires a prescription from a doctor or prescriber
Hypertension and heart failure
Official documents, adverse reaction reporting, and safety monitoring
Report a side effect
Submit a Yellow Card report to the MHRA
Official medicine documents
Safety monitoring data
Yellow Card reports
The MHRA Yellow Card scheme collects reports of suspected side effects from healthcare professionals and patients. View the Drug Analysis Profile (iDAP) for real-world adverse reaction data.
View Drug Analysis Profile
Suspected adverse reactions reported for Losartan
Browse all iDAP reports
Interactive Drug Analysis Profiles for all medicines
Report a side effect
Submit a Yellow Card report to the MHRA
Data from the MHRA Yellow Card scheme. A reported reaction does not necessarily mean the medicine caused it. Contains public sector information licensed under the Open Government Licence v3.0.
EudraVigilance
The European Medicines Agency (EMA) collects suspected adverse reaction reports from across the EU/EEA through the EudraVigilance system. Search for safety data on this medicine.
View EudraVigilance report
Suspected adverse reactions reported for Losartan
About EudraVigilance
Learn about EU pharmacovigilance and safety monitoring
EudraVigilance data is published by the European Medicines Agency (EMA). A suspected adverse reaction is not necessarily caused by the medicine.
51 branded products available
Part of the Cozaar brand family (generic: Losartan)
MHRA licensed products
View all licensed products for Losartan on the MHRA register
Cozaar 100mg tablets
Cozaar 100mg tablets
Cozaar 100mg tablets
Cozaar 100mg tablets
Losartan 100mg tablets
Losartan 100mg tablets
Losartan 100mg tablets
Losartan 100mg tablets
Losartan 100mg tablets
Losartan 100mg tablets
Losartan 100mg tablets
Losartan 100mg tablets
This is the NHS Drug Tariff indicative price used for reimbursement purposes. It may not reflect the price paid by patients or pharmacies.
View full Drug TariffSource: NHS Drug Tariff via NHSBSA. Derived from dm+d VMPP (Virtual Medicinal Product Pack) pricing data. Contains public sector information licensed under the Open Government Licence v3.0.
WHO defined daily dose (DDD)
50 mg
Not a recommended dose. The DDD is the assumed average maintenance dose per day for a drug used for its main indication in adults. It is a statistical measure used for research and comparison purposes only.
Source: WHO Collaborating Centre for Drug Statistics Methodology, distributed via NHS dm+d BNF mapping files. Contains public sector information licensed under the Open Government Licence v3.0.
Therapeutically similar medicines
Similarity based on WHO Anatomical Therapeutic Chemical (ATC) classification and NHS BNF section grouping. Source data: NHS dm+d via TRUD (OGL v3.0), WHO ATC/DDD Index.
NHS prescribing volume and spending trends
Clinical guidelines and formulary information
British National Formulary
Losartan
Source: British National Formulary, NICE. Joint Formulary Committee. Contains public sector information licensed under the Open Government Licence v3.0.
Check stock at pharmacies and supply information
Pharmacy stock checkers
Search for this medicine at major UK pharmacy chains. These links open the retailer's own website — results depend on their current online catalogue.
Supply & product information
Official product databases and supply status monitoring
Pharmacy links redirect to the retailer's own search and do not represent real-time stock levels. emc (electronic medicines compendium) is operated by Datapharm Ltd. Shortage information sourced from NHS Specialist Pharmacy Service (SPS), sps.nhs.uk.
Codes for healthcare professionals and prescribing systems
These codes are used by healthcare IT systems and prescribers to identify this medicine.
NHS UK identifiers
Browse tools
SNOMED CT and dm+d codes from NHS TRUD (Technology Reference data Update Distribution), licensed under the Open Government Licence v3.0. BNF codes from NHS Business Services Authority (NHSBSA). ATC codes from the WHO Collaborating Centre for Drug Statistics Methodology (whocc.no).
Active and completed clinical studies from ClinicalTrials.gov
Source: ClinicalTrials.gov, a database of the U.S. National Library of Medicine (NLM), National Institutes of Health (NIH). Data accessed via ClinicalTrials.gov API v2. Trial information is provided for research purposes and does not constitute medical advice.
Pharmacology and chemical data from DrugBank
Key facts
Drug status
Approved
Major interactions
53 found
Half-life
1.5-2.5 hours
Mechanism
Losartan reversibly and competitively prevents angiotensin II binding to the AT1…
Food interactions
2 warnings
Human targets
2 targets
Data: DrugBank · CC BY-NC 4.0
Pharmacokinetics at a glance
Absorption
33%
[A1033][L7423][L7426]
Losartan has a Tmax of 1 hour and the active metabolite has a Tmax of 3-4 hours.
[A1033][L7423][L7426]…
Half-life
1.5-2.5 hours
[A1033]
Protein binding
98.6-98.8%
[A1033]
Volume of distribution
17.9L
[A1033]
Metabolism
14%
[A1033]…
Elimination
4%
[L7423][L7426]…
Clearance
600mL/min
[A1033]…
Pharmacokinetic data: DrugBank · CC BY-NC 4.0
[L7423]
Losartan with hydrochlorothiazide is indicated to treat hypertension and to reduce the risk of stroke in patients with hypertension and left ventricular hypertrophy (though this benefit may not extend to patients with African heritage).
[L7426][L45663]
Known interactions with other medications. Always consult a healthcare professional.
Showing 50 of 1143 interactions
[L7423][L7426]
In humans the TDLO for men is 10mg/kg/2W and for women is 1mg/kg/1D.
[L7441]
Symptoms of overdose are likely to include hypotension, tachycardia, or bradycardia due to vagal stimulation.
[L7423][L7426]
Supportive treatment should be instituted for symptomatic hypotension.
[L7423][L7426]
Hemodialysis will not remove losartan or its active metabolite due to their high rates of protein binding.
[L7423][L7426]
Angiotensin II would otherwise bind to the AT1 receptor and induce vasoconstriction, raising blood pressure.[L7423][L7426]
How the body processes this drug — absorption, distribution, metabolism, and elimination
[A1033][L7423][L7426]
Losartan has a Tmax of 1 hour and the active metabolite has a Tmax of 3-4 hours.
[A1033][L7423][L7426]
Taking losartan with food decreases the Cmax but does only results in a 10% decrease in the AUC of losartan and its active metabolite.
[A1033][L7423][L7426]
A 50-80mg oral dose of losartan leads to a Cmax of 200-250ng/mL.
[A1033]
[A1033]
[A1033]
[A1033]
[A1033]
Losartan can also be hydroxylated to an inactive metabolite, P1.
[A1033]
Approximately 14% of losartan is metabolized to E-3174.
[A1033]
Losartan can be metabolized by CYP3A4, CYP2C9, and CYP2C10.
[A1033]
Losartan can also be glucuronidated by UGT1A1, UGT1A3, UGT1A10, UGT2B7, and UGT 2B17.
[A415]
[L7423][L7426]
Oral radiolabelled losartan is 35% recovered in urine and 60% in feces.
[L7423][L7426]
Intravenous radiolabelled losartan is 45% recovered in urine and 50% in feces.
[L7423][L7426]
[A1033]
E-3174, the active metabolite, has a total plasma clearance of 50mL/min and a renal clearance of 25mL/min.
[A1033]
Proteins and enzymes this drug interacts with in the body
PMID:10388848 PMID:2163695 PMID:2163696 PMID:8662939 PMID:9774108
Upon EPO stimulation, EPOR dimerizes triggering the JAK2/STAT5 signaling cascade (By similarity). In some cell types, can also activate STAT1 and STAT3 .
PMID:11756159
May also activate the LYN tyrosine kinase (By similarity)
PMID:15611106 PMID:1567413 PMID:25913193 PMID:26420482 PMID:30639100 PMID:32079768 PMID:8987975
The activated receptor in turn couples to G-alpha proteins G(q) (GNAQ, GNA11, GNA14 or GNA15) and thus activates phospholipase C and increases the cytosolic Ca(2+) concentrations, which in turn triggers cellular responses such as stimulation of protein kinase C PMID:15611106
Enzymes involved in drug metabolism — important for understanding drug interactions
Proteins that transport this drug across cell membranes
PMID:2897240 PMID:35970996 PMID:8898203 PMID:9038218 PMID:35507548
Catalyzes the flop of phospholipids from the cytoplasmic to the exoplasmic leaflet of the apical membrane. Participates mainly to the flop of phosphatidylcholine, phosphatidylethanolamine, beta-D-glucosylceramides and sphingomyelins .
PMID:8898203
Energy-dependent efflux pump responsible for decreased drug accumulation in multidrug-resistant cells PMID:2897240 PMID:35970996 PMID:9038218
PMID:11669456 PMID:11907186 PMID:14675047 PMID:22108572 PMID:23832370 PMID:28534121 PMID:9950961
Mediates the uptake of OA across the basolateral side of proximal tubule epithelial cells, thereby contributing to the renal elimination of endogenous OA from the systemic circulation into the urine .
PMID:9887087
Functions as a biopterin transporters involved in the uptake and the secretion of coenzymes tetrahydrobiopterin (BH4), dihydrobiopterin (BH2) and sepiapterin to urine, thereby determining baseline levels of blood biopterins .
PMID:28534121
Transports prostaglandin E2 (PGE2) and prostaglandin F2-alpha (PGF2-alpha) and may contribute to their renal excretion .
PMID:11907186
Also mediates the uptake of cyclic nucleotides such as cAMP and cGMP .
PMID:26377792
Involved in the transport of neuroactive tryptophan metabolites kynurenate (KYNA) and xanthurenate (XA) and may contribute to their secretion from the brain .
PMID:22108572 PMID:23832370
May transport glutamate .
PMID:26377792
Also involved in the disposition of uremic toxins and potentially toxic xenobiotics by the renal organic anion secretory pathway, helping reduce their undesired toxicological effects on the body .
PMID:11669456 PMID:14675047
Uremic toxins include the indoxyl sulfate (IS), hippurate/N-benzoylglycine (HA), indole acetate (IA), 3-carboxy-4- methyl-5-propyl-2-furanpropionate (CMPF) and urate .
PMID:14675047 PMID:26377792
Xenobiotics include the mycotoxin ochratoxin (OTA) .
PMID:11669456
May also contribute to the transport of organic compounds in testes across the blood-testis-barrier PMID:35307651
PMID:12024214 PMID:22194875 PMID:35144162 PMID:35462902
Involved in renal reabsorption of urate and helps maintaining blood levels of uric acid .
PMID:12024214 PMID:22194875
Mediates urate uptake by an exchange with organic anions such as (S)-lactate and nicotinate, and inorganic anion Cl(-) .
PMID:12024214
Other inorganic anions such as Br(-), I(-) and NO3(-) may also act as counteranions that exchange for urate .
PMID:12024214
Also mediates orotate tubular uptake coupled with nicotinate efflux and to a lesser extent with lactate efflux, therefore displaying a potential role in orotate renal reabsorption .
PMID:21350910
Orotate transport is Cl(-)-dependent PMID:21350910
PMID:18327257 PMID:18701466 PMID:22647630 PMID:28083649 PMID:36749388
May have a residual high-affinity, low-capacity glucose and fructose transporter activity .
PMID:18327257 PMID:18701466 PMID:18842065
Transports urate at rates 45- to 60-fold faster than glucose .
PMID:18842065
Does not transport galactose .
PMID:28083649
May mediate small uptake of adenine but not of other nucleobases PMID:22647630
PMID:15791618 PMID:16332456 PMID:18985798 PMID:19228692 PMID:20010382 PMID:20398791 PMID:22262466 PMID:24711118 PMID:29507376 PMID:32203132
Transports taurine-conjugated bile salts more rapidly than glycine-conjugated bile salts .
PMID:16332456
Also transports non-bile acid compounds, such as pravastatin and fexofenadine in an ATP-dependent manner and may be involved in their biliary excretion PMID:15901796 PMID:18245269
Proteins that carry this drug through the body
PMID:19021548
Major calcium and magnesium transporter in plasma, binds approximately 45% of circulating calcium and magnesium in plasma (By similarity).
Potentially has more than two calcium-binding sites and might additionally bind calcium in a non-specific manner (By similarity). The shared binding site between zinc and calcium at residue Asp-273 suggests a crosstalk between zinc and calcium transport in the blood (By similarity). The rank order of affinity is zinc > calcium > magnesium (By similarity).
Binds to the bacterial siderophore enterobactin and inhibits enterobactin-mediated iron uptake of E.coli from ferric transferrin, and may thereby limit the utilization of iron and growth of enteric bacteria such as E.coli .
PMID:6234017
Does not prevent iron uptake by the bacterial siderophore aerobactin PMID:6234017
ATC C09CA01
ATC C09DA01
ATC C09DB06
Chemical identifiers
CAS, UNII, InChI Key and database cross-references
Show
Chemical identifiers
CAS, UNII, InChI Key and database cross-references
Linked compound data from DrugBank Open Data (CC BY-NC 4.0)
Losartan
Additional database identifiers
Drugs Product Database (DPD)
144
ChemSpider
3824
BindingDB
82258
PDB
LSN
Guide to Pharmacology
590
ZINC
ZINC000003873160
HUGO Gene Nomenclature Committee (HGNC)
HGNC:3416
GenAtlas
EPOR
GeneCards
EPOR
GenBank Gene Database
M60459
GenBank Protein Database
182245
Guide to Pharmacology
1718
UniProt Accession
EPOR_HUMAN
HUGO Gene Nomenclature Committee (HGNC)
HGNC:336
GenAtlas
AGTR1
GeneCards
AGTR1
GenBank Gene Database
M91464
GenBank Protein Database
179122
Guide to Pharmacology
34
UniProt Accession
AGTR1_HUMAN
HUGO Gene Nomenclature Committee (HGNC)
HGNC:2623
GenAtlas
CYP2C9
GeneCards
CYP2C9
GenBank Gene Database
AY341248
Guide to Pharmacology
1326
UniProt Accession
CP2C9_HUMAN
HUGO Gene Nomenclature Committee (HGNC)
HGNC:2637
GenAtlas
CYP3A4
GeneCards
CYP3A4
GenBank Gene Database
M18907
Guide to Pharmacology
1337
UniProt Accession
CP3A4_HUMAN
HUGO Gene Nomenclature Committee (HGNC)
HGNC:2621
GeneCards
CYP2C19
GenBank Gene Database
M61854
GenBank Protein Database
181344
Guide to Pharmacology
1328
UniProt Accession
CP2CJ_HUMAN
HUGO Gene Nomenclature Committee (HGNC)
HGNC:12530
GeneCards
UGT1A1
GenBank Gene Database
M57899
GenBank Protein Database
184473
Guide to Pharmacology
2990
UniProt Accession
UD11_HUMAN
HUGO Gene Nomenclature Committee (HGNC)
HGNC:12535
GeneCards
UGT1A3
GenBank Gene Database
M84127
GenBank Protein Database
340135
UniProt Accession
UD13_HUMAN
HUGO Gene Nomenclature Committee (HGNC)
HGNC:12531
GeneCards
UGT1A10
GenBank Gene Database
U89508
GenBank Protein Database
2039362
UniProt Accession
UD110_HUMAN
HUGO Gene Nomenclature Committee (HGNC)
HGNC:12554
GeneCards
UGT2B7
GenBank Gene Database
J05428
GenBank Protein Database
340080
UniProt Accession
UD2B7_HUMAN
HUGO Gene Nomenclature Committee (HGNC)
HGNC:12547
GeneCards
UGT2B17
GenBank Gene Database
U59209
GenBank Protein Database
3287473
UniProt Accession
UDB17_HUMAN
HUGO Gene Nomenclature Committee (HGNC)
HGNC:2622
GenAtlas
CYP2C8
GeneCards
CYP2C8
GenBank Gene Database
M17397
Guide to Pharmacology
1325
UniProt Accession
CP2C8_HUMAN
HUGO Gene Nomenclature Committee (HGNC)
HGNC:399
GenAtlas
ALB
GeneCards
ALB
GenBank Gene Database
V00494
GenBank Protein Database
28590
UniProt Accession
ALBU_HUMAN
HUGO Gene Nomenclature Committee (HGNC)
HGNC:40
GenAtlas
ABCB1
GeneCards
ABCB1
GenBank Gene Database
M14758
GenBank Protein Database
307180
Guide to Pharmacology
768
UniProt Accession
MDR1_HUMAN
HUGO Gene Nomenclature Committee (HGNC)
HGNC:10970
GenAtlas
hROAT1
GeneCards
SLC22A6
GenBank Gene Database
AF057039
GenBank Protein Database
3831566
Guide to Pharmacology
1025
UniProt Accession
S22A6_HUMAN
HUGO Gene Nomenclature Committee (HGNC)
HGNC:17989
GeneCards
SLC22A12
Guide to Pharmacology
1031
UniProt Accession
S22AC_HUMAN
HUGO Gene Nomenclature Committee (HGNC)
HGNC:13446
GeneCards
SLC2A9
UniProt Accession
GTR9_HUMAN
HUGO Gene Nomenclature Committee (HGNC)
HGNC:42
GenAtlas
ABCB11
GeneCards
ABCB11
GenBank Gene Database
AF091582
GenBank Protein Database
3873243
Guide to Pharmacology
778
UniProt Accession
ABCBB_HUMAN
International reference pricing
Reference pricing from DrugBank. Prices are indicative and may not reflect current UK costs.
Source: DrugBank. Used under CC BY-NC 4.0 academic licence for non-commercial purposes.
Patent information
2 active patents, 4 expired
Source: DrugBank · CC BY-NC 4.0. Patent data sourced from national patent offices. Expiry dates may not reflect extensions, regulatory exclusivity periods, or legal challenges.
DrugBank citations
If you use DrugBank data in your research, please cite the following publications: